Crossmark

Posaconazole versus fluconazole as primary antifungal prophylaxis for patients at high risk of invasive fungal infections receiving allogeneic hematopoietic stem cell transplantation

Crossref DOI link: https://doi.org/10.1038/s41409-025-02589-z

Published Online: 2025-04-16

Published Print: 2025-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Letailleur, Valentin

Jullien, Maxime https://orcid.org/0000-0001-6915-6570
Garnier, Alice

Peterlin, Pierre

Vantyghem, Sophie

Fourmont, Aude-Marie

Guillaume, Thierry https://orcid.org/0000-0001-5482-8565
Chevallier, Patrice https://orcid.org/0000-0003-3142-5581
Le Bourgeois, Amandine https://orcid.org/0000-0003-0522-6976
License Information

Text and Data Mining valid from 2025-04-16

Version of Record valid from 2025-04-16
More Information

Article History

Received: 18 October 2024

Revised: 25 March 2025

Accepted: 1 April 2025

First Online: 16 April 2025

Competing interests

: The authors declare no competing interests.

: All methods were performed in accordance with the relevant guidelines and regulations. Ethics committee was not requested for this study because the design was a retrospective comparison of two antifungal prophylaxis strategies for allo-HSCT recipients at two different periods of time. No experimental drug was given and antifungal strategies were supported by ECIL guidelines that have evolved over the years. However, all patients provided informed consent for collection of their personal data.

Document is current

Any future updates will be listed below